Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
Vasomune Therapeutics, Inc., ("Vasomune"), a clinical-stage biopharmaceutical company, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application to develop Pegevongitide (AV-001) for use in the acute resuscitation of severely burned patients. Pegevongitide, an injectable Tie2 agonist that blocks vascular leak, is currently being researched for the prevention and treatment of acute respiratory distress syndrome (ARDS) (NCT05123755).
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients
A groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis.
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study
Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, announced today that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) to escalate to the high-dose cohort in their AV001-004 Phase 2a Study, NCT05123755.
Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001
Vasomune Therapeutics, Inc., has announced today that the US Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections. AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor which plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.
American Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit
Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, has been selected by the American Thoracic Society to showcase its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit (RIS). Vasomune’s lead drug candidate AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of this receptor plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space. Vasomune’s Scientific co-founder, Dr. Harold Kim, will speak on May 18th, at 11:30 AM PT, at the Manchester Grand Hyatt, San Diego, CA. (RIS Program Agenda can be found here).
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced today that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study.
Vasomune and AnGes Announce First Patient Enrolled in Phase 2a Clinical Study Evaluating AV-001 for the Treatment of Severe COVID-19 Disease
Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced today it has dosed the first patient in the Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. AV-001 is a novel pegylated peptide targeting the Tie2 receptor designed to activate the angiopoietin/Tie2 signaling pathway to normalize the vasculature.
Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic
Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced today it has received a Peer-Reviewed Medical Research Program (PRMRP) Clinical Trial Award (CTA) grant for US $6.4 million from the U.S. Department of Defense (DOD). In addition, the company is receiving advisory services and research and development funding of up to $2.8 Million from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
